| CRITICAL OUTCOME TECHNOLOGIES INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120077820 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER - The present invention is directed to methods of use of a compound of Formula I: | 03-29-2012 |
| 20110281887 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER - The present invention is directed to methods of use of a compound of Formula I: | 11-17-2011 |
| 20110152281 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER - The invention relates to a compound of Formula (I) and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein X is selected from S or O; R | 06-23-2011 |
| 20100015140 | Inhibitor Compounds and Cancer Treatment Methods - A synergistically effective combination of an anti-cancer agent and a therapeutic compound, such as an mTOR-Rictor complex inhibitor, a Serine 473 phosphorylation inhibitor, an AKT2 inhibitor, or a combination thereof, for use in the treatment of cancer, and methods and uses thereof. Also included are methods and uses of a thiosemicarbazone for treating a cancer in a mammal in need thereof characterized by over-expression of RAS, by an EGFR mutation, and/or by over-expression of AKT2. | 01-21-2010 |
| 20090298855 | Protein Tyrosine Kinase Inhibitors - The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: | 12-03-2009 |
